Related Experiment Video

Updated: May 9, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Efficacy of carvedilol in pediatric heart failure

Alex Hørby Christensen1, Diane Fatkin

  • 1Molecular Cardiology Division, Victor Chang Cardiac Research Institute, 405 Liverpool Street, Darlinghurst, New South Wales 2010, Australia.

Future Cardiology
|July 10, 2013
PubMed

Insights

Carvedilol may benefit pediatric heart failure patients with dilated cardiomyopathy. This study showed improvements in heart function and biomarkers, but further research is needed due to study limitations.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Pharmacology

Background:

  • The role of beta-blockers in pediatric heart failure remains unclear.
  • Dilated cardiomyopathy is a significant cause of heart failure in children.

Purpose of the Study:

  • To evaluate the efficacy and safety of carvedilol in pediatric patients with chronic heart failure due to dilated cardiomyopathy.
  • To assess the impact of carvedilol on clinical outcomes and cardiac function.

Main Methods:

  • A prospective, randomized-controlled study involving pediatric patients with dilated cardiomyopathy.
  • Patients received either oral carvedilol (up to 0.8 mg/kg/day) plus conventional therapy or conventional therapy alone for 6 months.
  • Primary endpoints included Ross score, echocardiographic parameters, brain natriuretic peptide levels, and a composite clinical endpoint.

Main Results:

  • Carvedilol treatment showed favorable effects on Ross score, left ventricular function, and brain natriuretic peptide levels compared to the control group.
  • The control group also demonstrated improvement, though less pronounced than in the carvedilol group.
  • Composite clinical endpoints were similar between the carvedilol-treated and control groups. Only one serious adverse event was reported.

Conclusions:

  • Carvedilol may offer a potential benefit when added to conventional therapy for pediatric patients with dilated cardiomyopathy and chronic heart failure.
  • Study design limitations necessitate cautious interpretation of the findings.
  • Further research is warranted to confirm the role of carvedilol in this patient population.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...